In vitro evaluation of E-4695, a new fluoro-naphthyridine.
Compound E-4695, a C-7 azetidinyl fluoro-naphthyridine, was compared to six structurally related quinolones and was generally two- to four-fold more active than ciprofloxacin. E-4695 was particularly active against Staphylococcus aureus (MIC90 0.06 mg/l), Staphylococcus haemolyticus (MIC90 0.5 mg/l), Klebsiella spp. (MIC90 less than or equal to 0.015 mg/l), Serratia marcescens (MIC90 0.06 mg/l), Acinetobacter spp. (MIC90 less than or equal to 0.015 mg/l), Pseudomonas aeruginosa (MIC90 0.5 mg/l), Xanthomonas maltophilia (MIC90 0.5 mg/l), and Neisseria gonorrhoeae (MIC90 less than or equal to 0.001 mg/l). This new quinolone-like drug requires further investigations to confirm these promising in vitro findings.
Jones
R N
RN
Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City 52242.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001384:Azetidines / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002939:Ciprofloxacin / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D015365:Enoxacin / Q000494:pharmacology; D016576:Fleroxacin / Q000494:pharmacology; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000494:pharmacology*; D009643:Norfloxacin / Q000494:pharmacology; D015242:Ofloxacin / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001384:Azetidines; D024841:Fluoroquinolones; D009287:Naphthyridines; D015363:Quinolones; C076875:E 4695; D015365:Enoxacin; D002939:Ciprofloxacin; D015242:Ofloxacin; C053091:lomefloxacin; D009643:Norfloxacin; D016576:Fleroxacin